Yoshiyuki Ohtomo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yoshiyuki Ohtomo has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Shuichiro Fujinaga
Division of Nephrology, Saitama Children’s Medical Center, Saitama, Japan
7 shared publications Yuichiro Yamashiro
Juntendo University School of Medicine
7 shared publications- Naoto Nishizaki
Department of Pediatrics Juntendo University Urayasu Hospital Chiba Japan
6 shared publications Daisuke Umino
Department of Pediatrics and Adolescent Medicine, Faculty of Medicine, Juntendo University, Tokyo, Japan
4 shared publications- Toshiaki Shimizu
Department of Pediatrics, Juntendo University Faculty of Medicine, Tokyo, Japan
4 shared publications - Amane Endo
Department of Pediatrics and Adolescent Medicine Juntendo University Graduate School of Medicine Tokyo Japan
3 shared publications
Latest Publications
- 1 January 2026
- Published by Wiley in Pediatrics International
- Vol. 68 (1)
Nocturnal Enuresis as a Presenting Feature of Chronic Kidney Disease Associated With Bilateral Renal Hypoplasia
- 1 January 2026
- Published by Wiley in Pediatrics International
- Vol. 68 (1)
Nocturnal Enuresis as a Presenting Feature of Chronic Kidney Disease Associated With Bilateral Renal Hypoplasia
- 1 January 2025
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e70000
Inhibition of renal fibrosis via Nrf2 activators for unilateral ureteral obstruction in a rat model
Background: Reactive oxygen species aggravate renal fibrosis, prompting the activation of nuclear factor erythroid 2‐related factor 2 (Nrf2), a key mediator in the cellular response to oxygen stress. Nrf2 exerts renoprotective effects by upregulating antioxidant response element (ARE)‐dependent genes that antagonize renal fibrosis. Elucidating mechanisms to attenuate renal fibrosis in children is essential for developing therapeutic interventions. This study aimed to examine the renoprotective effects of Nrf2 activators on ARE action in rats with unilateral ureteral obstruction (UUO)‐induced renal injury. Methods: The time course of Nrf2 was evaluated in 8‐week‐old male Sprague–Dawley rats with UUO, with or without Nrf2 activators (bardoxolone methyl) for 2 weeks postoperatively. Kidney tissues were collected on Days 7 and 14 post‐surgery. Renoprotective effects were examined using real‐time polymerase chain reaction (RT‐PCR) and histopathological analyses of kidney samples. Results: Nrf2 activators reduced the interstitial fibrotic area in UUO kidneys, causing a substantial decline in ED‐1‐positive cell infiltration and transforming growth factor‐β expression. RT‐PCR revealed that Nrf2 activators suppressed the expression of renal fibrotic factors and promoted the expression of ARE‐dependent genes. Moreover, immunostaining for Nrf2 demonstrated increased nuclear translocation and activation induced by Nrf2 activators. Conclusions: Nrf2 activators induced nuclear translocation and activation of Nrf2, resulting in upregulation of ARE‐dependent genes. Although the function of Nrf2 in children is often unknown, this study may lead to future progress in oxidation and antioxidant function in children.
- 1 January 2025
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e70000
Inhibition of renal fibrosis via Nrf2 activators for unilateral ureteral obstruction in a rat model
Background: Reactive oxygen species aggravate renal fibrosis, prompting the activation of nuclear factor erythroid 2‐related factor 2 (Nrf2), a key mediator in the cellular response to oxygen stress. Nrf2 exerts renoprotective effects by upregulating antioxidant response element (ARE)‐dependent genes that antagonize renal fibrosis. Elucidating mechanisms to attenuate renal fibrosis in children is essential for developing therapeutic interventions. This study aimed to examine the renoprotective effects of Nrf2 activators on ARE action in rats with unilateral ureteral obstruction (UUO)‐induced renal injury. Methods: The time course of Nrf2 was evaluated in 8‐week‐old male Sprague–Dawley rats with UUO, with or without Nrf2 activators (bardoxolone methyl) for 2 weeks postoperatively. Kidney tissues were collected on Days 7 and 14 post‐surgery. Renoprotective effects were examined using real‐time polymerase chain reaction (RT‐PCR) and histopathological analyses of kidney samples. Results: Nrf2 activators reduced the interstitial fibrotic area in UUO kidneys, causing a substantial decline in ED‐1‐positive cell infiltration and transforming growth factor‐β expression. RT‐PCR revealed that Nrf2 activators suppressed the expression of renal fibrotic factors and promoted the expression of ARE‐dependent genes. Moreover, immunostaining for Nrf2 demonstrated increased nuclear translocation and activation induced by Nrf2 activators. Conclusions: Nrf2 activators induced nuclear translocation and activation of Nrf2, resulting in upregulation of ARE‐dependent genes. Although the function of Nrf2 in children is often unknown, this study may lead to future progress in oxidation and antioxidant function in children.
- 1 January 2022
- Published by Wiley in Pediatrics International
- Vol. 64 (1) , e15253
Granulomatous vasculitis of the esophagus in a girl with odynophagia
- 1 January 2022
- Published by Wiley in Pediatrics International
- Vol. 64 (1) , e15253
Granulomatous vasculitis of the esophagus in a girl with odynophagia
- Open Access
- 21 January 2021
- Published by Springer Nature in CEN Case Reports
- Vol. 10 (3) , 359-363
An extremely mild clinical course in a case with LAMB2-associated nephritis diagnosed with next-generation sequencing
Biallelic pathogenic variants in the laminin β2 (LAMB2) gene, which encodes laminin β2, are associated with Pierson syndrome characterized by a congenital nephrotic syndrome that rapidly progresses to end-stage renal disease, distinct ocular maldevelopment with bilateral microcoria, and neurodevelopmental deficits. However, the phenotypic spectrum of LAMB2-associated disorder is broader than expected, and cases with milder phenotypes such as isolated congenital or infantile nephrotic syndrome have also been reported. We report a patient with LAMB2-associated renal disorder showing an extremely mild phenotype. A 5-year-old girl presented with asymptomatic proteinuria and hematuria detected by urinalysis screening. She had been previously healthy without any additional renal symptoms. The serum albumin and creatinine levels were normal. Renal biopsy revealed minor glomerular abnormalities with occasional focal mesangial proliferation. Electron microscopy showed no structural changes in the glomerular basement membrane. Targeted sequencing of podocyte-related genes using next-generation sequencing was performed. As a result, previously reported biallelic pathogenic variants of the truncating variant (c.5073_5076dupCCAG) and a splice site variant (c.3797 + 5G > A) in the LAMB2 gene were detected, and the patient was diagnosed with LAMB2-associated renal disorder. Interestingly, a previously reported case with this splicing variant also showed an atypically mild phenotype. We suggest that clinicians should consider LAMB2-associated nephritis as an important differential diagnosis in children with asymptomatic proteinuria and microscopic hematuria if there is no structural change in the glomerular basement membrane. A comprehensive gene-screening system using next-generation sequencing is useful for diagnosing these atypical cases with isolated urine abnormalities.
- 21 January 2021
- Published by Springer Nature in CEN Case Reports
- Vol. 10 (3) , 359-363
Open AccessAn extremely mild clinical course in a case with LAMB2-associated nephritis diagnosed with next-generation sequencing
Biallelic pathogenic variants in the laminin β2 (LAMB2) gene, which encodes laminin β2, are associated with Pierson syndrome characterized by a congenital nephrotic syndrome that rapidly progresses to end-stage renal disease, distinct ocular maldevelopment with bilateral microcoria, and neurodevelopmental deficits. However, the phenotypic spectrum of LAMB2-associated disorder is broader than expected, and cases with milder phenotypes such as isolated congenital or infantile nephrotic syndrome have also been reported. We report a patient with LAMB2-associated renal disorder showing an extremely mild phenotype. A 5-year-old girl presented with asymptomatic proteinuria and hematuria detected by urinalysis screening. She had been previously healthy without any additional renal symptoms. The serum albumin and creatinine levels were normal. Renal biopsy revealed minor glomerular abnormalities with occasional focal mesangial proliferation. Electron microscopy showed no structural changes in the glomerular basement membrane. Targeted sequencing of podocyte-related genes using next-generation sequencing was performed. As a result, previously reported biallelic pathogenic variants of the truncating variant (c.5073_5076dupCCAG) and a splice site variant (c.3797 + 5G > A) in the LAMB2 gene were detected, and the patient was diagnosed with LAMB2-associated renal disorder. Interestingly, a previously reported case with this splicing variant also showed an atypically mild phenotype. We suggest that clinicians should consider LAMB2-associated nephritis as an important differential diagnosis in children with asymptomatic proteinuria and microscopic hematuria if there is no structural change in the glomerular basement membrane. A comprehensive gene-screening system using next-generation sequencing is useful for diagnosing these atypical cases with isolated urine abnormalities.
- 14 May 2019
- Published by Wiley in Pediatrics International
- Vol. 61 (5) , 530
Bright light therapy as a non‐pharmacological treatment for refractory enuresis
- 14 May 2019
- Published by Wiley in Pediatrics International
- Vol. 61 (5) , 530
Bright light therapy as a non‐pharmacological treatment for refractory enuresis
- Open Access
- 22 November 2018
- Published by Wiley in Pediatrics International
- Vol. 60 (11) , 997
Pathophysiology and treatment of enuresis: Focus on sleep
- 22 November 2018
- Published by Wiley in Pediatrics International
- Vol. 60 (11) , 997
Open AccessPathophysiology and treatment of enuresis: Focus on sleep
- 24 April 2017
- Published by Wiley in Pediatrics International
- Vol. 59 (6) , 711-713
Clonidine may have a beneficial effect on refractory nocturnal enuresis
Background: Although the evidence‐based treatment for nocturnal enuresis is established, nearly one‐third of patients are still enuretic with desmopressin, anti‐cholinergic treatment and alarm. The fourth option, imipramine, is limited because of the risk of cardiotoxicity on overdose. Clonidine, an α2‐adrenoceptor agonist that also has noradrenergic effects like imipramine, is a new option for refractory enuresis.Methods: A total of 148 patients (6–14 years of age; mean, 9.1 years) with refractory enuresis under desmopressin, anti‐cholinergic treatment and alarm were enrolled. The patients consisted of 100 boys and 48 girls, of whom 23 had monosymptomatic nocturnal enuresis and 125 had non‐monosymptomatic nocturnal enuresis. Clonidine 4 μg/kg/day (maximum, 75 μg/day) orally 30 min before bedtime was added and its effects were evaluated after 4 weeks of treatment.Results: A total of 83 patients (56.1%) achieved partial or complete response with the additional clonidine. No significant adverse reactions were noted.Conclusions: Clonidine could be an aid for refractory enuresis, although further randomized controlled trials are needed.
- 24 April 2017
- Published by Wiley in Pediatrics International
- Vol. 59 (6) , 711-713
Clonidine may have a beneficial effect on refractory nocturnal enuresis
Background: Although the evidence‐based treatment for nocturnal enuresis is established, nearly one‐third of patients are still enuretic with desmopressin, anti‐cholinergic treatment and alarm. The fourth option, imipramine, is limited because of the risk of cardiotoxicity on overdose. Clonidine, an α2‐adrenoceptor agonist that also has noradrenergic effects like imipramine, is a new option for refractory enuresis.Methods: A total of 148 patients (6–14 years of age; mean, 9.1 years) with refractory enuresis under desmopressin, anti‐cholinergic treatment and alarm were enrolled. The patients consisted of 100 boys and 48 girls, of whom 23 had monosymptomatic nocturnal enuresis and 125 had non‐monosymptomatic nocturnal enuresis. Clonidine 4 μg/kg/day (maximum, 75 μg/day) orally 30 min before bedtime was added and its effects were evaluated after 4 weeks of treatment.Results: A total of 83 patients (56.1%) achieved partial or complete response with the additional clonidine. No significant adverse reactions were noted.Conclusions: Clonidine could be an aid for refractory enuresis, although further randomized controlled trials are needed.
- 19 March 2017
- Published by Wiley in Pediatrics International
- Vol. 59 (3) , 383-384
Initial combination therapy with desmopressin, solifenacin, and alarm for monosymptomatic nocturnal enuresis
- 19 March 2017
- Published by Wiley in Pediatrics International
- Vol. 59 (3) , 383-384
Initial combination therapy with desmopressin, solifenacin, and alarm for monosymptomatic nocturnal enuresis
- 16 February 2017
- Published by Wiley in Pediatrics International
- Vol. 59 (6) , 704-710
Impaired nephrogenesis in neonatal rats with oxygen‐induced retinopathy
Background: Preterm neonates are born while nephrogenesis is ongoing, and are commonly exposed to factors in a hyperoxic environment that can impair renal development. Oxidative stress has also been implicated in the development of retinopathy of prematurity (ROP). The rat model of oxygen‐induced retinopathy (OIR) is the most clinically relevant model of ROP because its biologic features closely resemble those of ROP in preterm infants. We investigated impaired renal development in a rat model of OIR.Methods: Newborn Sprague–Dawley rats were maintained in either a normoxic (room air, 21% O2; control group) or a controlled hyperoxic (80% O2; OIR group) environment from birth to postnatal day (P) 12. All pups were then raised in room air from P12 to P19.Results: The hyperoxic environment led to significantly higher urinary excretion of 8‐hydroxy‐2′‐deoxyguanosine, a marker of oxidative DNA damage, and a reduction in nephrogenic zone width at P5 in OIR pups. Additionally, glomerular count was significantly reduced by 20% in the OIR group, and avascular and neovascular changes in the retina were observed only in the OIR group at P19. Messenger RNA levels of vascular endothelial growth factor‐A (VEGF‐A) and platelet‐derived growth factor‐β, essential angiogenic cytokines for glomerulogenesis, in the renal cortex were significantly lower at P5 and significantly higher at P19 in the OIR group compared with controls.Conclusion: Renal impairment was caused by exposure to a hyperoxic environment during nephrogenesis, and the pathology of the impaired nephrogenesis in this OIR model reflects the characteristics of ROP observed in preterm infants.
- 16 February 2017
- Published by Wiley in Pediatrics International
- Vol. 59 (6) , 704-710
Impaired nephrogenesis in neonatal rats with oxygen‐induced retinopathy
Background: Preterm neonates are born while nephrogenesis is ongoing, and are commonly exposed to factors in a hyperoxic environment that can impair renal development. Oxidative stress has also been implicated in the development of retinopathy of prematurity (ROP). The rat model of oxygen‐induced retinopathy (OIR) is the most clinically relevant model of ROP because its biologic features closely resemble those of ROP in preterm infants. We investigated impaired renal development in a rat model of OIR.Methods: Newborn Sprague–Dawley rats were maintained in either a normoxic (room air, 21% O2; control group) or a controlled hyperoxic (80% O2; OIR group) environment from birth to postnatal day (P) 12. All pups were then raised in room air from P12 to P19.Results: The hyperoxic environment led to significantly higher urinary excretion of 8‐hydroxy‐2′‐deoxyguanosine, a marker of oxidative DNA damage, and a reduction in nephrogenic zone width at P5 in OIR pups. Additionally, glomerular count was significantly reduced by 20% in the OIR group, and avascular and neovascular changes in the retina were observed only in the OIR group at P19. Messenger RNA levels of vascular endothelial growth factor‐A (VEGF‐A) and platelet‐derived growth factor‐β, essential angiogenic cytokines for glomerulogenesis, in the renal cortex were significantly lower at P5 and significantly higher at P19 in the OIR group compared with controls.Conclusion: Renal impairment was caused by exposure to a hyperoxic environment during nephrogenesis, and the pathology of the impaired nephrogenesis in this OIR model reflects the characteristics of ROP observed in preterm infants.
- 19 October 2016
- Published by Wiley in Pediatrics International
- Vol. 59 (2) , 181-184
Atomoxetine ameliorates nocturnal enuresis with subclinical attention‐deficit/hyperactivity disorder
Background: Recent studies have shown that incontinence and attention‐deficit/hyperactivity disorder (ADHD) coexist and there is an interaction between them. The treatment for nocturnal enuresis (NE) and ADHD, however, has not been established.Methods: At the first visit to the outpatient clinic, physical examination and history taking were carried out in 265 new patients with NE. After excluding the possibility of comorbid ADHD and related disorders, patients with monosymptomatic NE (MNE) were treated with desmopressin and/or alarm, and those with non‐monosymptomatic NE (NMNE) were treated with anti‐cholinergics and/or alarm. This 12 week treatment did not work in 65 patients, and they were re‐assessed for comorbid ADHD. A total of 24 were diagnosed with ADHD, and they were treated with atomoxetine (1.8 mg/kg/day) in addition to ongoing therapy for NE.Results: After 8 weeks of atomoxetine, the average wet nights per months was significantly decreased: 18.5–4.6 in the MNE group (P = 0.001), and 22.1–12.4 in the NMNE group (P = 0.0251). Overall, atomoxetine was beneficial in 19 of 24 patients.Conclusions: Atomoxetine may be a suitable option for refractory NE with comorbid ADHD.
- 19 October 2016
- Published by Wiley in Pediatrics International
- Vol. 59 (2) , 181-184
Atomoxetine ameliorates nocturnal enuresis with subclinical attention‐deficit/hyperactivity disorder
Background: Recent studies have shown that incontinence and attention‐deficit/hyperactivity disorder (ADHD) coexist and there is an interaction between them. The treatment for nocturnal enuresis (NE) and ADHD, however, has not been established.Methods: At the first visit to the outpatient clinic, physical examination and history taking were carried out in 265 new patients with NE. After excluding the possibility of comorbid ADHD and related disorders, patients with monosymptomatic NE (MNE) were treated with desmopressin and/or alarm, and those with non‐monosymptomatic NE (NMNE) were treated with anti‐cholinergics and/or alarm. This 12 week treatment did not work in 65 patients, and they were re‐assessed for comorbid ADHD. A total of 24 were diagnosed with ADHD, and they were treated with atomoxetine (1.8 mg/kg/day) in addition to ongoing therapy for NE.Results: After 8 weeks of atomoxetine, the average wet nights per months was significantly decreased: 18.5–4.6 in the MNE group (P = 0.001), and 22.1–12.4 in the NMNE group (P = 0.0251). Overall, atomoxetine was beneficial in 19 of 24 patients.Conclusions: Atomoxetine may be a suitable option for refractory NE with comorbid ADHD.